Panbela Therapeutics, Inc.: additional paid-in capital

What this measure means

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Exact concept: us-gaap:AdditionalPaidInCapital. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2011-12-31 to 2023-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Panbela Therapeutics, Inc.: total assets
• Panbela Therapeutics, Inc.: total liabilities
• Panbela Therapeutics, Inc.: stockholders equity
• Panbela Therapeutics, Inc.: cash and cash equivalents
• Panbela Therapeutics, Inc.: net income or loss
• Panbela Therapeutics, Inc.: operating cash flow
• Panbela Therapeutics, Inc.: revenue
• Panbela Therapeutics, Inc.: financing cash flow
• Panbela Therapeutics, Inc.: investing cash flow
• Panbela Therapeutics, Inc.: retained earnings or deficit
• Panbela Therapeutics, Inc.: basic weighted-average shares
• Panbela Therapeutics, Inc.: basic earnings per share
• Panbela Therapeutics, Inc.: diluted earnings per share
• Panbela Therapeutics, Inc.: income tax expense or benefit
• Panbela Therapeutics, Inc.: net property, plant and equipment
• Panbela Therapeutics, Inc.: share-based compensation expense
• Panbela Therapeutics, Inc.: operating income or loss
• Panbela Therapeutics, Inc.: current assets
• Panbela Therapeutics, Inc.: interest expense
• Panbela Therapeutics, Inc.: current liabilities
• Panbela Therapeutics, Inc.: current accounts payable
• Panbela Therapeutics, Inc.: net current accounts receivable
• Panbela Therapeutics, Inc.: gross profit
• Panbela Therapeutics, Inc.: cost of revenue
• Panbela Therapeutics, Inc.: research and development expense
• Panbela Therapeutics, Inc.: common shares outstanding
• Panbela Therapeutics, Inc.: accumulated other comprehensive income or loss
• Panbela Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Panbela Therapeutics, Inc.: other noncurrent assets
• Panbela Therapeutics, Inc.: accrued current liabilities
• Panbela Therapeutics, Inc.: net deferred tax assets
• Panbela Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Panbela Therapeutics, Inc.: comprehensive income or loss
• Panbela Therapeutics, Inc.: general and administrative expense
• Panbela Therapeutics, Inc.: depreciation expense
• Panbela Therapeutics, Inc.: other nonoperating income or expense
• Panbela Therapeutics, Inc.: nonoperating income or expense
• Panbela Therapeutics, Inc.: current income tax expense or benefit
• Panbela Therapeutics, Inc.: deferred income tax expense or benefit
• Panbela Therapeutics, Inc.: interest paid, net
• Panbela Therapeutics, Inc.: change in accounts receivable
• Panbela Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Panbela Therapeutics, Inc. / CIK 0001029125

Captured

2026-09-21T17:17:41.392Z

SEC response SHA-256

5fda5ff967a840ef3f57f70eeef789c92fe69418b24473bec9634b9f66bd5e2d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001029125.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))